Zhejiang Pu Li Pharma Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference ca38aeacba
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
56 acceptance records as first applicant, grouped into 31 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
依折麦布阿托伐他汀钙片(I)、(II) · No verified English name 2 records · Latest accepted 2026/07/02
Generic · 2
Fusidic Acid Cream 1 records · Latest accepted 2026/04/30
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2601022 | Generic | 2026/04/30 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Diclofenac Sodium Sustained Release Tablets 4 records · Latest accepted 2025/10/28
Supplement · 2Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2502205 | Supplement | 2025/10/28 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2501046 | Supplement | 2025/05/22 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2200119 | Generic | 2022/01/19 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2200118 | Generic | 2022/01/19 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Clarithromycin sustained-release tablets 1 records · Latest accepted 2025/04/16
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2501453 | Generic | 2025/04/16 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Lidocaine and Prilocaine Cream 2 records · Latest accepted 2025/01/04
Generic · 2
Mirabegron Extended-release Tablets 1 records · Latest accepted 2024/12/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404323 | Generic | 2024/12/12 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Adapalene Gel 1 records · Latest accepted 2024/11/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2403860 | Generic | 2024/11/12 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
比拉斯汀口崩片 · No verified English name 2 records · Latest accepted 2024/10/12
Generic · 2
Brexpiprazole Tablets 3 records · Latest accepted 2024/09/21
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2403142 | Generic | 2024/09/21 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2403141 | Generic | 2024/09/21 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2403140 | Generic | 2024/09/21 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
注射用PL002 · No verified English name 1 records · Latest accepted 2024/09/10
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2400936 | New drug | 2024/09/10 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
氯雷他定糖浆 · No verified English name 1 records · Latest accepted 2024/08/15
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2402652 | Generic | 2024/08/15 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Baloxavir Marboxil Tablets 2 records · Latest accepted 2024/08/15
Generic · 2
Diclofenac Diethylamine Emulgel 2 records · Latest accepted 2024/07/18
Generic · 2
Teicoplanin for Injection 1 records · Latest accepted 2023/12/30
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2303679 | Generic | 2023/12/30 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Fexofenadine Hydrochloride Oral Suspension 1 records · Latest accepted 2023/11/20
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2303171 | Generic | 2023/11/20 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Bilastine Tablets 1 records · Latest accepted 2023/09/15
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302493 | Generic | 2023/09/15 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Rupatadine Fumarate Tablets 1 records · Latest accepted 2023/09/08
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302416 | Generic | 2023/09/08 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
地氯雷他定口服溶液 · No verified English name 2 records · Latest accepted 2023/07/28
Generic · 2
Silodosin Capsules 1 records · Latest accepted 2023/05/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301298 | Generic | 2023/05/12 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Amiodarone Hydrochloride Injection 3 records · Latest accepted 2023/03/16
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300798 | Generic | 2023/03/16 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300797 | Generic | 2023/03/16 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300796 | Generic | 2023/03/16 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Calcium Levofolinate Injection 4 records · Latest accepted 2023/02/04
Generic · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300334 | Generic | 2023/02/04 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300333 | Generic | 2023/02/04 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300332 | Generic | 2023/02/04 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300331 | Generic | 2023/02/04 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Allopurinol Tablets 1 records · Latest accepted 2022/12/21
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2202092 | Generic | 2022/12/21 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Emtricitabine Capsules 1 records · Latest accepted 2022/10/26
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201829 | Generic | 2022/10/26 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Oseltamivir Phosphate Capsules 3 records · Latest accepted 2022/09/21
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201572 | Generic | 2022/09/21 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201571 | Generic | 2022/09/21 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201570 | Generic | 2022/09/21 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Oseltamivir Phosphate For Oral Suspension 1 records · Latest accepted 2022/09/16
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201546 | Generic | 2022/09/16 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
盐酸美金刚颗粒 · No verified English name 2 records · Latest accepted 2022/05/25
New drug · 2
利奈唑胺干混悬剂 · No verified English name 2 records · Latest accepted 2022/02/14
Generic · 2
Voriconazole for Oral Suspension 1 records · Latest accepted 2022/01/05
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2200006 | Generic | 2022/01/05 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Fluconazole for Oral Suspension 4 records · Latest accepted 2021/10/19
Generic · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2101895 | Generic | 2021/10/19 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2101894 | Generic | 2021/10/19 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2101893 | Generic | 2021/10/19 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2101892 | Generic | 2021/10/19 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
泊沙康唑干混悬剂 · No verified English name 1 records · Latest accepted 2021/07/02
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2101254 | New drug | 2021/07/02 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Oxcarbazepine Tablets 3 records · Latest accepted 2021/06/11
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2101290 | Generic | 2021/06/11 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2101289 | Generic | 2021/06/11 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2101288 | Generic | 2021/06/11 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| 依折麦布阿托伐他汀钙片(I)、(II) · No verified English name | CYHS2601566 | Generic | 2026/07/02 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| 依折麦布阿托伐他汀钙片(I)、(II) · No verified English name | CYHS2601565 | Generic | 2026/07/02 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| Fusidic Acid Cream | CYHS2601022 | Generic | 2026/04/30 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| Clarithromycin sustained-release tablets | CYHS2501453 | Generic | 2025/04/16 | Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
31 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Brexpiprazole Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20265318 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Brexpiprazole Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20265317 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Brexpiprazole Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20265319 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Mirabegron Extended-release Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20265329 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Baloxavir Marboxil Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20263286 | 2026/01/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Baloxavir Marboxil Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20263285 | 2026/01/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Teicoplanin for Injection | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20254617 | 2025/06/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 利奈唑胺干混悬剂 · No verified English name | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20253003 | 2025/01/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Amiodarone Hydrochloride Injection | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249443 | 2024/11/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Amiodarone Hydrochloride Injection | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249442 | 2024/11/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Silodosin Capsules | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249444 | 2024/11/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Calcium Levofolinate Injection | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249208 | 2024/10/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Calcium Levofolinate Injection | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249207 | 2024/10/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Calcium Levofolinate Injection | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249210 | 2024/10/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Calcium Levofolinate Injection | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249209 | 2024/10/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rupatadine Fumarate Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20249163 | 2024/10/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Allopurinol Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20244620 | 2024/08/05 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Emtricitabine Capsules | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20244493 | 2024/07/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oseltamivir Phosphate For Oral Suspension | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20244240 | 2024/06/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oseltamivir Phosphate Capsules | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20243536 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oseltamivir Phosphate Capsules | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20243535 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Fluconazole for Oral Suspension | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20234271 | 2023/10/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Voriconazole for Oral Suspension | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20234051 | 2023/08/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Diclofenac Sodium Sustained Release Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20233810 | 2023/06/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Diclofenac Sodium Sustained Release Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20233809 | 2023/06/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oxcarbazepine Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20233399 | 2023/04/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oxcarbazepine Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20233400 | 2023/04/04 | Not stated by source | CDE ↗ |
| Oxcarbazepine Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20233398 | 2023/04/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levofloxacin Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20213278 | 2021/04/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levofloxacin Tablets | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20213082 | 2021/01/30 | Not stated by source | CDE ↗ |
| Oseltamivir Phosphate Capsules | Zhejiang Pu Li Pharma Co., Ltd. romanized | Zhejiang Pu Li Pharma Co., Ltd. romanized | 国药准字H20243537 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
6 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Probucol Tablets | CYHS2600190 | Generic | 2026/01/16 | Shanxi Hua Xia Tai Kang Pharmaceuticals Group Co., Ltd. romanized; Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| Glucosamine Sulfate Capsules | CYHS2504457 | Generic | 2025/12/29 | Shanxi Hua Xia Tai Kang Pharmaceuticals Group Co., Ltd. romanized; Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| 积雪苷片 · No verified English name | CYZB2200858 | Supplement | 2022/08/01 | Hainan Pu Li Pharmaceutical Co., Ltd. romanized; Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| Azithromycin for Suspension | CYHB2250211 | Supplement | 2022/04/11 | Hainan Pu Li Pharmaceutical Co., Ltd. romanized; Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| Azithromycin for Suspension | CYHB2250210 | Supplement | 2022/04/11 | Hainan Pu Li Pharmaceutical Co., Ltd. romanized; Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
| Azithromycin for Suspension | CYHB2250209 | Supplement | 2022/04/11 | Hainan Pu Li Pharmaceutical Co., Ltd. romanized; Zhejiang Pu Li Pharma Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.